Figure 5.Comparison of the immunotherapeutic response of low- and high-risk HCC patients. (A) Comparison of immune checkpoint expression between the two subgroups. (B) Differences in TIDE scores in low- and high-risk individuals. (C–F) Differences in IPS scores in low- and high-risk individuals. (G) Differences in TMB in low- and high-risk individuals. (H) Kaplan-Meier survival curves of HCC patients in different TMB groups. (I) Kaplan-Meier survival curves in different risk scores and TMB subgroups.
